Antitumor activity of Enzastaurin (LY317615) in human tumor xenografts in vitro

被引：1
|
作者：
Maier, A.
Fiebig, H. H.
Thornton, D.
Lahn, M.
机构：
[1] Oncotest GmbH, Inst Expt Oncol, Freiburg, Germany
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(06)70621-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
616
引用
收藏
页码：186 / 186
页数：1
相关论文
共 50 条
  • [31] The oral protein-kinase C β inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines
    Neri, Antonino
    Marmiroli, Sandra
    Tassone, Pierfrancesco
    Lombardi, Luigia
    Nobili, Lucia
    Verdelli, Donata
    Civallero, Monica
    Cosenza, Maria
    Bertacchini, Jessika
    Federico, Massimo
    De Pol, Anto
    Deliliers, Giorgio Lambertenghi
    Sacchi, Stefano
    LEUKEMIA & LYMPHOMA, 2008, 49 (07) : 1374 - 1383
  • [32] The Direct Anti-Tumor Activity of Enzastaurin (LY317615.HCl) and Its Primary Metabolite (LY326020.HCl) Is Evident in Preclinical DLBCL Models Regardless of Molecular Subtype
    Graff, Jeremy R.
    McNulty, Ann M.
    Dumstorf, Chad
    Konicek, Bruce
    Hall, Chad
    Parsons, Stephen
    BLOOD, 2012, 120 (21)
  • [33] Antitumor activity of cabazitaxel in pediatric tumor xenografts
    Sidhu, Sukhvinder S.
    Malfilatre, Marc
    Janvier, Claire
    Boulcourt-Sambou, Elisabeth
    Vincent, Loic
    Calvet, Loreley
    Vrignaud, Patricia
    CANCER RESEARCH, 2012, 72
  • [34] The protein kinase Cβ-selective inhibitor, enzastaurin (LY317615.HCI), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts
    Graff, JR
    McNulty, AM
    Hanna, KR
    Konicek, BW
    Lynch, RL
    Bailey, SN
    Banks, C
    Capen, A
    Goode, R
    Lewis, JE
    Sams, L
    Huss, KL
    Campbell, RM
    Iversen, PW
    Neubauer, BL
    Brown, TJ
    Musib, L
    Geeganage, S
    Thornton, D
    CANCER RESEARCH, 2005, 65 (16) : 7462 - 7469
  • [35] Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)
    Podar, Klaus
    Raab, Marc S.
    Zhang, Jing
    McMillin, Douglas
    Breitkreutz, Iris
    Tai, Yu-Tzu
    Lin, Boris K.
    Munshi, Nikhil
    Hideshima, Teru
    Chauhan, Dharminder
    Anderson, Kenneth C.
    BLOOD, 2007, 109 (04) : 1669 - 1677
  • [36] Targeting PKC in multiple myeloma:: In vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCI).
    Raab, Marc S.
    Podar, Klaus
    Zhang, Jing
    McMillin, Douglas
    Breitkreutz, Iris
    Tai, Yu-Tzu
    Lin, Boris
    Ghobrial, Irene
    Munshi, Nikhil
    Hideshima, Teru
    Chauhan, Dharminder
    Anderson, Kenneth C.
    BLOOD, 2006, 108 (11) : 989A - 989A
  • [37] Effect of estrogen on cathepsin B activity and antitumor efficacy of paclitaxel poliglumex in human tumor xenografts
    Di Giovine, S.
    De Feudis, P.
    Torriani, D.
    Colella, G.
    Cassin, M.
    Piazzoni, L.
    Bastrup, U.
    Natangelo, M.
    Pezzoni, G.
    Singer, J.
    EJC SUPPLEMENTS, 2006, 4 (12): : 191 - 191
  • [38] Enzastaurin (LY317615.HCI) and Its Primary Metabolite (LY326020.HCI) Exert Antitumor Effects in Diffuse Large B Cell Lymphoma Through Multiple Mechanisms, Most Notably Control of 4EBP1 Activity
    Graff, J.
    McNulty, A. M.
    Dumstorf, C.
    Parsons, S.
    Konicek, B. W.
    Hall, C.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 151 - 152
  • [39] ANTITUMOR-ACTIVITY OF HEXAMETHYLMELAMINE ON HUMAN TUMOR XENOGRAFTS SERIALLY TRANSPLANTED IN NUDE-MICE
    KUBOTA, T
    TANINO, H
    WATANABE, M
    KITAJIMA, M
    ANTICANCER RESEARCH, 1994, 14 (6B) : 2521 - 2524
  • [40] DEVELOPMENT OF A METHOD FOR ASSESSING ANTITUMOR ACTIVITY OF CHEMOTHERAPEUTIC-AGENTS USING HUMAN TUMOR XENOGRAFTS
    COBB, LM
    MITCHLEY, BC
    CANCER CHEMOTHERAPY REPORTS PART 1, 1974, 58 (05): : 645 - 651
12345